Sai Life Sciences Limited has informed the Exchange about Investor Presentation
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences reported FY25 revenue of ₹1,695 Cr, up 16% YoY from ₹1,465 Cr, driven by growth in both CDMO (63% of revenue) and CRO (37% of revenue) segments. EBITDA grew to ₹425 Cr with margin expanding sharply to 25% (from 20%), while material margin improved to 73%. Profit after tax surged 105% to ₹170 Cr, supported by operating leverage and lower finance costs. The company completed its planned ₹720 Cr debt repayment, moving to a net cash position (Net Debt/EBITDA at -0.2x). Capex for the year stood at ₹408 Cr, with the launch of a new Peptide Research Centre and expansion of manufacturing and discovery capabilities.
Strong margin expansion, 105% PAT growth, and the shift to a net cash position signal robust execution and improving return ratios (ROCE up to 12.3%). This should be viewed positively by shareholders, though the high capex intensity continues to warrant monitoring.